Abstract
Introduction: Two important pathogenic species within the genus Burkholderia, namely Burkholderia pseudomallei (Bpm) and Burkholderia mallei (Bm), are the causative agents of the life-threatening diseases melioidosis and glanders, respectively. Due to their high mortality rate and potential for aerosolization, they have gained interest as potential biothreat agents and are classified as Tier 1 Select Agents. Areas covered: The manuscript provides an overview of the literature covering the efforts taken in the last 10 years to develop new therapeutics measures against both Bpm and Bm, with attention on novel therapeutic agents. Expert Opinion: As a result of the complicated antibiotic regimens necessary to treat these infections, development of novel therapeutics is needed to treat both diseases. In recent years, the understanding of the pathogenesis of Burkholderia has improved significantly and so have the efforts to develop novel therapeutic agents with high efficacy, either alone, or in combination with conventional antibiotics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1319-1332 |
| Number of pages | 14 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 19 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2 2019 |
| Externally published | Yes |
Keywords
- Burkholderia mallei
- Burkholderia pseudomallei
- antibiotics
- antibodies
- glanders
- melioidosis
- phages
- therapeutics
- vaccines
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry